Yüklüyor......
Targeting CD20: teaching an old dog new tricks
Rituximab was the first monoclonal antibody used for the treatment of a malignancy. In the 22 years since initial approval, it has become a vital component of therapy for a multitude of B-cell malignancies. Within the last several years, however, there has been a robust development of novel agents t...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913507/ https://ncbi.nlm.nih.gov/pubmed/31808844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000031 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|